HeartSciences' MyoVista Wavelet ECG. [Photo: HeartSciences]
Southlake-based HeartSciences, which closed on a $6.375M IPO in June, applies AI-based technology to an ECG to detect cardiac dysfunction—one of the earliest signs of heart disease. The company says this can't be diagnosed by current conventional ECGs, making its MyoVista Wavelet ECG device a potential game changer.
CEO Andrew Simpson says adding this diagnostic information to an ECG "addresses a significant unmet need in the market with an estimated 100 million-plus ECG tests performed annually in the U.S.A. alone."